Institute and Department of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Eur Rev Med Pharmacol Sci. 2020 Sep;24(17):8997-9007. doi: 10.26355/eurrev_202009_22842.
The authors performed a systematic review and meta-analysis to investigate the role of rs72613567 within hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) in liver diseases.
Relevant studies on the effects of HSD17B13 rs72613567 on liver diseases were found using the PubMed, Web of Science, and Embase databases, up to March 2020. The keywords "HSD17B13", "polymorphism", "variant" and "rs72613567" were used. Odds ratios (OR) and 95% confidence interval (CI) were extracted or estimated from each eligible study. A random-effects model was applied to pool results.
We included a large population for the assessment of any liver disease (n=564702), cirrhosis (n=559834), and hepatocellular carcinoma (HCC) (n=183179), respectively. The results demonstrated that the TA allele of HSD17B13 rs72613567 could provide substantial protection from these disorders (any liver diseases: pooled OR=0.73, 95% CI=0.61-0.87; liver cirrhosis: pooled OR=0.81, 95% CI=0.76-0.88; HCC: pooled OR=0.64, 95% CI=0.53-0.77). In addition, four studies were summarized based on the histological features of nonalcoholic fatty liver disease (NAFLD). HSD17B13 rs72613567 showed a tendency towards decreased inflammation, reduced fibrosis, and milder disease severity in NAFLD.
Our study highlights that HSD17B13 rs72613567 is an important protective factor in multiple categories of liver diseases.
作者进行了一项系统评价和荟萃分析，旨在研究羟甾体 17-β 脱氢酶 13（HSD17B13）内 rs72613567 对肝脏疾病的作用。
使用 PubMed、Web of Science 和 Embase 数据库，检索截至 2020 年 3 月关于 HSD17B13 rs72613567 对肝脏疾病影响的相关研究。关键词为“ HSD17B13”、“多态性”、“变异”和“ rs72613567”。从每项合格研究中提取或估计比值比（OR）和 95％置信区间（CI）。应用随机效应模型对结果进行合并。
我们分别纳入了评估任何肝脏疾病（n=564702）、肝硬化（n=559834）和肝细胞癌（HCC）（n=183179）的大人群。结果表明，HSD17B13 rs72613567 的 TA 等位基因可显著预防这些疾病（任何肝脏疾病：合并 OR=0.73，95％CI=0.61-0.87；肝硬化：合并 OR=0.81，95％CI=0.76-0.88；HCC：合并 OR=0.64，95％CI=0.53-0.77）。此外，基于非酒精性脂肪性肝病（NAFLD）的组织学特征，我们总结了四项研究。HSD17B13 rs72613567 显示出降低 NAFLD 炎症、减少纤维化和疾病严重程度较轻的趋势。
我们的研究强调，HSD17B13 rs72613567 是多种肝脏疾病的重要保护因素。
